INTRODUCTION
5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent that inhibits cancer cell growth and initiates apoptosis by targeting thymidylate synthase (TS), and by direct incorporation of 5-FU metabolites into DNA and RNA [1] . 5-FU-based chemotherapy improves the overall and disease-free survival of patients with solid cancers, including colorectal cancer. However, de novo and acquired chemoresistance are major obstacles to the success of 5-FU-based chemotherapy. The overexpression of TS has been shown to be a major 5-FU resistance-inducing factor [2] . However, the overexpression of TS does not account for all non-responding tumors in colorectal cancer patients treated with 5-FU [3] . High expression levels of dihydropyrimidine dehydrogenase (DPD), the genetic status of p53, NF-kB, DNA mismatch-repair genes, and cell cycle disturbance have also been reported to be associated thesurgery.or.kr with 5-FU resistance [3] [4] [5] [6] [7] . Thus, the mechanisms of resistance to 5-FU are believed to be multi-factorial.
The up-regulation of cyclooxygenase (COX)-2 expression is an early and key oncogenic event in human colon neoplasia, and occurs in 85% of colon cancers and in 50% of colon adenomas [8] . It has also been suggested that the overexpression of COX-2 in colorectal cancer is associated with tumor growth, angiogenesis, lymphatic invasion, and metastasis [9] . Nonsteroidal anti-inflammatory drugs (NSAIDs) targeting COX-2 have been shown to directly shrink colon adenomas in some patients and to mediate cancer cell apoptosis [10, 11] . Similarly, in mice, the genetic inactivation of COX-2 blocks murine intestinal adenoma development [12, 13] . Most actions of COX-2 are known to be mediated by prostaglandin E2 (PGE2). Furthermore, it has been reported that the antitumor effects of 5-FU are increased when it is co-treated with COX-2 inhibitors [14, 15] . However, little is known about the role of COX-2 in acquired resistance to 5-FU in colon cancer cells.
In the present study, we investigated whether COX-2-derived PGE2 contributes to acquired resistance to 5-FU in colon cancer cells.
METHODS

Cell culture
The SNU-C5 colon cancer cell line (KCLB no. 0000C5) was obtained from the Korean Cell Line Bank (Seoul, Korea) and cultured at 37 o C in a 5% CO2 atmosphere using Roswell Park Memorial Institute (RPMI) 1640 medium (Invitrogen, Gland Island, NY, USA) with 10% heat inactivated fetal bovine serum (FBS, Sigma-Aldrich Co., St.
Louis, MO, USA). The 5-fluorouracil-resistant SNU-C5 subline, SNU-C5/5FUR, was selected from its parental cell line, SNU-C5, after chronic exposure to an intermittent dose schedule of 5-FU (Sigma-Aldrich Co.) in order to facilitate the expression of the resistant phenotype. 5-FU was initially added at 1 × IC50 (50% inhibitory concentration, 17.5 μM), and subsequently increased at a rate of 50%.
Finally, the cells were cultured in a fixed 5-FU concentration (140 μM) [16] . When the sensitivities of SNU-C5 and SNU-C5/5FUR cells to 5-FU were determined using 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays, the IC50 values of SNU-C5 and SNU-C5/5FUR cells were 7.8 μM and 337.4 μM, respectively, i.e., SNU-C5/5FUR cells were 43.6 times more resistant to 5-FU than SNU-C5 cells.
Cytotoxicity assays
The in vitro cytotoxicities of 5-FU and/or meloxicam (COX-2 inhibitor, Sigma-Aldrich Co.) were determined by using MTT assays [17] . Ninety-μL aliquots of cell suspen- 
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PGE2 levels in culture media were measured by using a general radioimmunoassay procedure adapted from Cetta and Goetz [18] . Briefly, in preliminary studies, prostaglandin was recovered from culture media using extraction fluid (ethyl acetate:isopropanol:0.05 N HCl = 3:
3:1); the recovery rate was relatively constant (92 ± 3%, n = 9). When PGE2 was assayed in increasing aliquots of unextracted medium (25, 50 and 100 μL), potency estimates were parallel to a linearly transformed dose response curve. Accordingly, medium samples were assayed directly without extraction. Samples were quantified using a liquid scintillation analyzer. Duplicate hormone standards (5 to 1,000 pg) were included in each assay. The between-and within-assay variation coefficients for PGE2 were 7.3% and 6.5%, respectively.
Statistical analysis
Statistically significant differences between multiple groups were analyzed using the Student's t-test or the paired Student's t-test (SPSS version 12.0, SPSS Inc., Chicago, IL, USA). The level of significance was set at P ＜ 0.05 in all cases.
RESULTS
Expression of COX-1, COX-2 in SNU-C5 and SNU-C5/5FUR cells
By quantitative RT-PCR, the expression levels of COX-1 and COX-2 were significantly higher in SNU-C5/5FUR than in SNU-C5. Also the ratio of COX-2 to COX-1 was higher in the resistant cells than in the parental cells (Fig. 1). thesurgery.or.kr Compare PGE2 levels after meloxicam (100 μM) with control in SNU-C5/5FUR, all of which have P-values less than 0.01.
Up-regulation of PGE 2 levels in SNU-C5/5FUR and inhibitory effect of meloxicam on PGE 2 synthesis
PGE2 levels present in culture media supernatants after incubation for 12 hours were determined by ELISA. For untreated cells, PGE2 levels were significantly higher in SNU-C5/5FUR than in SNU-C5 (P ＜ 0.01). After treatment with meloxicam, PGE2 levels were significantly and dose-dependently reduced in SNU-C5/5FUR cells (P ＜ 0.01), but not in SNU-C5 cells (Fig. 2) . (Fig. 3) .
Cytotoxicities of SNU-C5 and SNU-C5/5FUR to 5-FU and/or meloxicam
Up-regulation of VEGF mRNA expression in SNU-C5/5FUR and the inhibitory effect of meloxicam on VEGF mRNA expression
Despite the above-mentioned PGE2 level increases in SNU-C5/5FUR cells, meloxicam showed little effect on overcoming resistance to 5-FU in cell culture. Thus, we investigated VEGF expression, as VEGF is the most powerful stimulator for angiogenesis, and is required for tumor growth and metastasis. VEGF mRNA levels in untreated SNU-C5/5FUR cells were higher than that in SNU-C5 cells, Ten μM to 500 μM of meloxicam down-regulated these levels in SNU-C5/5FUR cells in a dose-dependent manner.
However, paradoxically meloxicam dose-dependently increased VEGF mRNA levels in SNU-C5/WT cells (Fig. 4) . 
DISCUSSION
The present study demonstrates that the expressions of COX-2, PGE2, and VEGF were up-regulated in the 5-FU resistant colon cancer cells rather than in the parental cells. [19, 20] . In the present study, we used the colon cancer cell line, SNU-C5, and its 5-FU resistant derivative, the SNU-C5/5FUR cell line. It is known that p53 is mutated and non-functional in SNU-C5 cells [21] .
It is known that COX-2 is induced by a variety of stimuli, such as, oncogenes (HER-2/neu), growth factors (EGF), tumor promoters (phorbol esters and bile acid), and chemotherapy [12] . Moreover, microtubule-interfering agents (paclitaxel, vincristine, etc) are known to induce COX-2 in cancer cells [22, 23] . However, it has not been determined as to whether COX-2 is induced by 5-FU in 5-FU-resistant cancer cells. It has been reported that COX-2 mRNA expression is increased by 5-FU alone or in combination in human solid tumors, e.g., esophageal, breast, ovarian, and colorectal tumors [24] . In addition, significant increases in COX-2 expression have been reported in rectal cancer after preoperative chemoradiotherapy thesurgery.or.kr It is believed that neovascularization is required for a tumor to grow to ＞2 to 3 mm [29] . Chang et al. [30] reported that PGE2 stimulates the expressions of angiogenic regulatory genes in mammary tumor cells isolated from COX-2 transgenic mice, which demonstrates that COX-2-derived PGE2 is a potent inducer of angiogenic switch during mammary cancer progression. In the present study, VEGF up-regulation was observed in SNU-C5/ 5FUR cells, and this up-regulation was recovered adding meloxicam, a COX-2 inhibitor, which suggests that COX-2-derived PGE2 plays an important role in the angiogenic switching that occurs during the acquisition of 5-FU resistance in colon cancer. Furthermore, the present study demonstrates that meloxicam exerts an anti-angiogenic effect by inhibiting PGE2 synthesis at a dose of 10 μM, which is relatively compatible with therapeutic levels. However, we had one unexpected result, i.e., SNU-C5 cells (which are chemonaïve colon cancer cells) express little VEGF or COX-2 in the basal state, but these cells were found to express VEGF after meloxicam treatment. Similarly, Ueno et al. [31] reported that treatment with celecoxib (a COX-2 inhibitor) decreased VEGF serum levels immediately after treatment but later increased its levels in serum and plasma in breast cancer patients. Thus further studies are required to determine how COX-2 inhibitors participate in VEGF production in cancer cells and tissues that do not express COX-2.
In conclusion, the authors demonstrate that COX-2 derived PGE2 is up-regulated and COX-2 inhibitor may have anti-angiogenic effect in the colon cancer cells resistant to 5-FU.
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